Cardiotoxicity of Anti-cancer Therapies: From Bench to Bedside
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".
Deadline for manuscript submissions: closed (1 April 2024) | Viewed by 746
Special Issue Editors
Interests: cardio-oncology; cardiotoxicity; heart failure; pulmonary hypertension
Interests: characterization of molecular targets involved in tumour survival, resistance, progression, and immune escape; characterization of molecular mechanisms involved in cancer therapy-induced cardiotoxicity and evaluation of a clinical approach to prevent heart failure
Special Issue Information
Dear Colleagues,
As the world’s population grows older, the coexistence of cancer and cardiovascular diseases is becoming more common. In particular, cardiotoxicity induced by chemotherapy and targeted therapies is becoming a significant health problem for oncological patients. These antineoplastic treatments may induce adverse cardiovascular effects such as the impairment of cardiac contractility, which can be either transient or irreversible. Furthermore, cancer treatment is associated with life-threatening arrhythmia, ischemia, infarction, and damage to cardiac valves, the conduction system, and the pericardium. In addition, the presence of overt cardiovascular diseases might limit therapeutic options in cancer patients.
The onset of cardiotoxicity may depend on the class, dose, route, and duration of the administration of antineoplastic drugs, as well as on individual risk factors. There is an urgent need for early diagnostic tools and cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages.
This Special Issue welcomes contributions regarding the cellular and molecular mechanisms of cancer therapies, as well as the prevention, diagnosis, and treatment of the cardiotoxic effects of cancer therapies. Original research and review articles are particularly welcomed.
Dr. Alessandra Cuomo
Dr. Michele Russo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiotoxicity
- cardio-oncology
- anticancer therapy
- chemotherapy
- cardioprotection
- oncological treatment
- cardio-prevention
